Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 353

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 353
---
 are denominated in US Dollars. The warrants are classified
equity settled derivative financial liabilities and accounted for in the same way as those detailed above. The financial liability is
valued using the Black-Scholes option pricing model. The exercise price of the outstanding options is $1,903.40.

The following table
details the outstanding warrants and options over ADSs and ordinary shares recognised as equity settled derivative financial liabilities
as at June 30, 2024, December 31, 2023 and also the movement in the year:

| Schedule of warrants outstanding |     | At December 
    31, 2022 |     | Lapsed |   |     |   Granted |     |        At 
  December 
  31, 2023 |     | Lapsed |   |     |   Granted |     | Exercised  |   |     |      At June 30, 
 2024   unaudited |
|:---------------------------------|:----|------------:|:----|:-------|:--|:----|----------:|:----|----------:|:----|:-------|:--|:----|----------:|:----|:-----------|:--|:----|-----------------:|
| ADSs warrants                    |     |             |     |        |   |     |           |     |           |     |        |   |     |           |     |            |   |     |                  |
| May 2024 grant                   |     |           – |     | –      |   |     |         – |     |         – |     | –      |   |     | 6,054,230 |     | –          |   |     |        6,054,230 |
| December 2023 grant              |     |           – |     |        |   |     | 6,000,126 |     | 6,000,126 |     | –      |   |     |         – |     | (4,282,895 | ) |     |        1,717,231 |
| May 2023 grant                   |     |           – |     |        |   |     |   276,689 |     |   276,689 |     | –      |   |     |         – |     | –          |   |     |          276,689 |
| May 2020 grant                   |     |         838 |